KR20230124671A - 위암의 예방 및 조기 발견을 위한 바이오마커 시그니처(들) - Google Patents

위암의 예방 및 조기 발견을 위한 바이오마커 시그니처(들) Download PDF

Info

Publication number
KR20230124671A
KR20230124671A KR1020237024923A KR20237024923A KR20230124671A KR 20230124671 A KR20230124671 A KR 20230124671A KR 1020237024923 A KR1020237024923 A KR 1020237024923A KR 20237024923 A KR20237024923 A KR 20237024923A KR 20230124671 A KR20230124671 A KR 20230124671A
Authority
KR
South Korea
Prior art keywords
gastric cancer
biomarkers
levels
lep
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237024923A
Other languages
English (en)
Korean (ko)
Inventor
엘리에뜨 꺄미유 뚜아띠
발레리 미셸
도미니끄 라마끄
깡땅 기에 기아네또
티보 두스
마리에뜨 마똥도
Original Assignee
앵스티띠 파스퇴르
유니베르시떼 드 베르사이유 쎙 깡뗑 앙 이브렝
아시스땅스 퍼블리끄-오삐또 드 빠리
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앵스티띠 파스퇴르, 유니베르시떼 드 베르사이유 쎙 깡뗑 앙 이브렝, 아시스땅스 퍼블리끄-오삐또 드 빠리 filed Critical 앵스티띠 파스퇴르
Publication of KR20230124671A publication Critical patent/KR20230124671A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57446—
    • G01N33/57484—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/20—ICT specially adapted for the handling or processing of medical references relating to practices or guidelines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioethics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020237024923A 2020-12-21 2021-12-21 위암의 예방 및 조기 발견을 위한 바이오마커 시그니처(들) Pending KR20230124671A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20306649.3 2020-12-21
EP20306649 2020-12-21
PCT/EP2021/087155 WO2022136472A1 (en) 2020-12-21 2021-12-21 Biomarkers signature(s) for the prevention and early detection of gastric cancer

Publications (1)

Publication Number Publication Date
KR20230124671A true KR20230124671A (ko) 2023-08-25

Family

ID=74184396

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237024923A Pending KR20230124671A (ko) 2020-12-21 2021-12-21 위암의 예방 및 조기 발견을 위한 바이오마커 시그니처(들)

Country Status (7)

Country Link
US (1) US20240053343A1 (https=)
EP (1) EP4263872A1 (https=)
JP (1) JP2024502253A (https=)
KR (1) KR20230124671A (https=)
CN (1) CN116867911A (https=)
CA (1) CA3202252A1 (https=)
WO (1) WO2022136472A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4497005A1 (en) * 2022-03-23 2025-01-29 Serum Detect, Inc. Biomarker signatures indicative of early stages of cancer
CN116500276A (zh) * 2023-04-26 2023-07-28 苏州大学附属儿童医院 一种usf2表达量的检测方法及应用
CN118483437B (zh) * 2024-07-15 2024-10-18 济南市中心医院 区分普通高血压与难治性高血压的生物标志物及其应用
CN118645252B (zh) * 2024-08-16 2025-01-28 杭州和壹基因科技有限公司 基于深度学习的疾病风险评估方法及系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101272207B1 (ko) * 2008-02-06 2013-06-07 아지노모토 가부시키가이샤 위암의 평가 방법, 및 위암 평가 장치, 위암 평가 방법, 위암 평가 시스템, 위암 평가 프로그램 및 기록 매체
WO2012167112A2 (en) * 2011-06-01 2012-12-06 Illumina, Inc. Gastric cancer biomarkers
CN104204807B (zh) * 2012-01-20 2016-11-09 阿德莱德研究及创新控股有限公司 用于胃癌的生物标志物及其应用
EP2857520A1 (en) 2013-10-03 2015-04-08 Institut Pasteur Method for in vitro investigating mitochondrial dna levels in a biological sample, kits and uses thereof
CN105572354B (zh) * 2014-10-17 2018-02-02 广州瑞博奥生物科技有限公司 一种检测早期胃癌的抗体芯片试剂盒

Also Published As

Publication number Publication date
US20240053343A1 (en) 2024-02-15
CA3202252A1 (en) 2022-06-30
CN116867911A (zh) 2023-10-10
EP4263872A1 (en) 2023-10-25
WO2022136472A1 (en) 2022-06-30
JP2024502253A (ja) 2024-01-18

Similar Documents

Publication Publication Date Title
JP6630766B2 (ja) 膵臓癌診断用組成物およびこれを用いた膵臓癌診断方法
KR20230124671A (ko) 위암의 예방 및 조기 발견을 위한 바이오마커 시그니처(들)
US10509034B2 (en) Bladder carcinoma biomarkers
US20230063827A1 (en) Methods and Compositions for the Diagnosis of Ovarian Cancer
Di Meo et al. Searching for prognostic biomarkers for small renal masses in the urinary proteome
WO2019010429A1 (en) METHODS OF DIAGNOSING PANCREATIC CANCER
JP5422785B2 (ja) 質量分析法を利用した複数癌腫の血液検出のための方法および生物マーカー
WO2019158825A1 (en) Xrcc5 as biomarker for prostate cancer
US20220326241A1 (en) Proteogenomic methods for diagnosing cancer
KR102599695B1 (ko) 마커 사람 부고환 단백질 4 (he4) 기반의 폐 선암 재발의 발견 방법 및 관련 용도
US10359426B2 (en) Use of isocitrate dehydrogenase 1 as a diagnostic and prognostic biomarker and therapeutic target for lung cancers
JP5429725B1 (ja) 前立腺癌の進行度の評価方法、前立腺癌の検出方法、および検査キット
JP2023531860A (ja) 肺癌検出用バイオマーカー
KR102879745B1 (ko) 갑상선 종양의 감별진단용 바이오마커 및 이의 용도
US20250362300A1 (en) Novel biomarkers for diagnosing pancreatic cancer
CN110554196A (zh) 胰腺癌预后标志物及其应用
CN120405156A (zh) 一种用于肺癌分型的血清蛋白生物标志物及其应用
KR20250078101A (ko) 유두암종유사핵모양비침습소포종양의 진단 또는 예후 예측용 바이오마커 및 이를 이용한 갑상선 종양의 치료를 위한 정보제공방법
CN119193833A (zh) Sctag在食管癌的早期诊断、预后评估和复发预警中的应用
Montero-Calle et al. ARTICLE INFO Article history

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000